Australia markets open in 6 hours 57 minutes

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9750-0.0350 (-1.74%)
As of 11:03AM EST. Market open.

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200

Full-time employees317

Key executives

NameTitlePayExercisedYear born
Dr. Jacqueline E. Shea Ph.D.CEO, Pres & Director698.85k908.99k1966
Mr. Peter D. KiesChief Financial Officer686.51k271.76k1963
Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer672.26kN/A1967
Ben MatoneDirector of Investor RelationsN/AN/AN/A
Mr. Robert L. Crotty J.D.Gen. CounselN/AN/A1974
Ms. Asli GevgililiChief HR OfficerN/AN/AN/A
Mr. E. J. Brandreth MBASr. VP of Quality AssuranceN/AN/AN/A
Dr. Jeffrey SkolnikSr. VP of Clinical Devel.N/AN/AN/A
Mr. Robert J. Juba Jr.Sr. VP of Biological Manufacturing & Clinical Supply ManagementN/AN/AN/A
Mr. Daniel JordanSr. VP of Device Manufacturing OperationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate governance

Inovio Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 November 2022 is 4. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.